Cargando…
Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease
BACKGROUND: Intraputamenal glial cell line-derived neurotrophic factor (GDNF), administered every 4 weeks to patients with moderately advanced Parkinson’s disease, did not show significant clinical improvements against placebo at 40 weeks, although it significantly increased [(18)F]DOPA uptake throu...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597995/ https://www.ncbi.nlm.nih.gov/pubmed/30829619 http://dx.doi.org/10.3233/JPD-191576 |